Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Cash & Equivalents (2020 - 2026)

IceCure Medical has reported Cash & Equivalents over the past 7 years, most recently at $8.1 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 34.35% year-over-year to $8.1 million; the TTM value through Mar 2026 reached $8.1 million, up 34.35%, while the annual FY2025 figure was $8.9 million, 17.62% up from the prior year.
  • Cash & Equivalents was $8.1 million for Q1 2026 at IceCure Medical, down from $8.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $23.7 million in Q4 2022 and bottomed at $6.0 million in Q1 2025.
  • The 5-year median for Cash & Equivalents is $8.5 million (2025), against an average of $10.8 million.
  • Year-over-year, Cash & Equivalents crashed 55.48% in 2023 and then surged 34.35% in 2026.
  • Over 5 years, Cash & Equivalents stood at $23.7 million in 2022, then tumbled by 55.48% to $10.5 million in 2023, then decreased by 28.19% to $7.6 million in 2024, then grew by 17.62% to $8.9 million in 2025, then decreased by 8.79% to $8.1 million in 2026.
  • The last three reported values for Cash & Equivalents were $8.1 million (Q1 2026), $8.9 million (Q4 2025), and $6.0 million (Q1 2025) per Business Quant data.